CC BY-NC-ND 4.0 · J Neurol Surg Rep 2023; 84(04): e124-e128
DOI: 10.1055/a-2166-5688
Original Report

CIC-DUX4 Sarcoma Involving the Skull Base: A Rare Presentation and Review of the Literature

1   Department of Otorhinolaryngology – Head and Neck Surgery at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
2   Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
,
Leila J. Mady
1   Department of Otorhinolaryngology – Head and Neck Surgery at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
,
Alec M. Jacobson
3   Department of Pathology and Laboratory Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
,
Christopher H. Rassekh
1   Department of Otorhinolaryngology – Head and Neck Surgery at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
› Author Affiliations

Abstract

Background CIC-DUX4 sarcoma is a rare, aggressive tumor that is difficult to diagnose. Although it is closely related to Ewing's sarcoma, each is a distinct pathologic entity and both have been previously reported in the skin, lymph nodes, and viscera. We report the first description of CIC-DUX4 involving the posterior cranial fossa and review the distinctive symptomatology, morphology, immunoprofile, and genetic signature that differentiate this rare tumor.

Case Report A 32-year-old man presented with an enlarging right lateral neck mass, progressive hoarseness, and orofacial pain. Biopsy revealed a high-grade undifferentiated malignant neoplasm. Imaging demonstrated an 8-cm mass in the right neck extending to the skull base and abutting the carotid sheath, in addition to pulmonary nodules and pelvic lymphadenopathy. Despite initial response to chemotherapy, he experienced disease progression and underwent surgical resection, radical neck dissection, and brachytherapy. Definitive pathologic diagnosis was achieved with next-generation sequencing. Within weeks of treatment, he developed symptoms reflecting progression of disease involving the neck, posterior cranial fossa, and lung. Adjuvant chemotherapy was planned, but the patient succumbed to his disease prior to initiation of further therapy.

Conclusion CIC-DUX4 sarcomas are uncommon and can progress rapidly. Diagnosis requires either fluorescence in situ hybridization or next-generation sequencing. Due to its rarity, there is no standard-of-care treatment for this tumor and further investigations are needed to understand disease behavior and develop targeted therapeutic modalities.



Publication History

Received: 15 February 2022

Accepted: 23 December 2022

Accepted Manuscript online:
05 September 2023

Article published online:
13 October 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Gleeson M, Herbert A, Richards A. Management of lateral neck masses in adults. BMJ 2000; 320 (7248) 1521-1524
  • 2 Pynnonen MA, Gillespie MB, Roman B. et al. Clinical practice guideline: evaluation of the neck mass in adults. Otolaryngol Head Neck Surg 2017; 157 (2_suppl): S1-S30
  • 3 Richkind KE, Romansky SG, Finklestein JZ. t(4;19)(q35;q13.1): a recurrent change in primitive mesenchymal tumors?. Cancer Genet Cytogenet 1996; 87 (01) 71-74
  • 4 Yoshimoto T, Tanaka M, Homme M. et al. CIC-DUX4 induces small round cell sarcomas distinct from Ewing sarcoma. Cancer Res 2017; 77 (11) 2927-2937
  • 5 Antonescu CR, Owosho AA, Zhang L. et al. Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases. Am J Surg Pathol 2017; 41 (07) 941-949
  • 6 Kawamura-Saito M, Yamazaki Y, Kaneko K. et al. Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum Mol Genet 2006; 15 (13) 2125-2137
  • 7 Specht K, Sung YS, Zhang L, Richter GHS, Fletcher CD, Antonescu CR. Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion-positive round cell tumors compared to EWSR1-rearranged Ewing sarcomas: further evidence toward distinct pathologic entities. Genes Chromosomes Cancer 2014; 53 (07) 622-633
  • 8 Graham C, Chilton-MacNeill S, Zielenska M, Somers GR. The CIC-DUX4 fusion transcript is present in a subgroup of pediatric primitive round cell sarcomas. Hum Pathol 2012; 43 (02) 180-189
  • 9 Okimoto RA, Wu W, Nanjo S. et al. CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs. J Clin Invest 2019; 129 (08) 3401-3406
  • 10 Tamada H, Kobayashi M, Sano K. et al. Ultrastructure of CIC-DUX4 sarcoma: the first pathological report. Ultrastruct Pathol 2020; 44 (02) 237-244
  • 11 Yamamoto H, Horiuchi S, Adachi Y. et al. Expression of ets-related transcriptional factor E1AF is associated with tumor progression and over-expression of matrilysin in human gastric cancer. Carcinogenesis 2004; 25 (03) 325-332
  • 12 Horiuchi S, Yamamoto H, Min Y, Adachi Y, Itoh F, Imai K. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J Pathol 2003; 200 (05) 568-576
  • 13 Davidson B, Gotlieb WH, Ben-Baruch G. et al. Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases: a clinicopathologic study. Gynecol Oncol 2000; 77 (01) 35-43
  • 14 de Launoit Y, Chotteau-Lelievre A, Beaudoin C. et al. The PEA3 group of ETS-related transcription factors. Role in breast cancer metastasis. Adv Exp Med Biol 2000; 480: 107-116
  • 15 Roberts P, Browne CF, Lewis IJ. et al. 12q13 abnormality in rhabdomyosarcoma. A nonrandom occurrence?. Cancer Genet Cytogenet 1992; 60 (02) 135-140
  • 16 Yoshida A, Goto K, Kodaira M. et al. CIC-rearranged sarcomas: a study of 20 cases and comparisons with Ewing sarcomas. Am J Surg Pathol 2016; 40 (03) 313-323
  • 17 Yoshida A, Arai Y, Kobayashi E. et al. CIC break-apart fluorescence in-situ hybridization misses a subset of CIC-DUX4 sarcomas: a clinicopathological and molecular study. Histopathology 2017; 71 (03) 461-469
  • 18 Italiano A, Sung YS, Zhang L. et al. High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes Chromosomes Cancer 2012; 51 (03) 207-218
  • 19 Haidar A, Arekapudi S, DeMattia F, Abu-Isa E, Kraut M. High-grade undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: emerging entities of soft tissue tumors with unique histopathologic features: a case report and literature review. Am J Case Rep 2015; 16: 87-94
  • 20 Brčić I, Brodowicz T, Cerroni L. et al. Undifferentiated round cell sarcomas with CIC-DUX4 gene fusion: expanding the clinical spectrum. Pathology 2020; 52 (02) 236-242
  • 21 Camille A, Anne-Sophie B, Cécile P. et al. Sarcoma with CIC-DUX4 gene fusion: case report of kidney tumor location in a 12-year-old boy. Pediatr Dev Pathol 2018; 21 (04) 406-410
  • 22 Yamada S, Muto J, De Leon JCA. et al. Primary spinal intramedullary Ewing-like sarcoma harboring CIC-DUX4 translocation: a similar cytological appearance as its soft tissue counterpart but no lobulation in association with desmoplastic stroma. Brain Tumor Pathol 2020; 37 (03) 111-117
  • 23 Donahue JE, Yakirevich E, Zhong S. et al. Primary spinal epidural CIC-DUX4 undifferentiated sarcoma in a child. Pediatr Dev Pathol 2018; 21 (04) 411-417
  • 24 Maejima E, Mitsui H, Ohnuma T. et al. Case of CIC-DUX4 sarcoma of the skin: histological simulant of epithelioid angiosarcoma. J Dermatol 2021; 48 (12) e594-e595
  • 25 Donthi D, Malik P, Prenshaw KL, Hong H. A rare case of round cell sarcoma with cic-dux4 mutation mimicking a phlegmon: review of literature. Am J Case Rep 2020; 21: e925683
  • 26 Rekhi B, Kembhavi P, Mishra SN, Shetty O, Bajpai J, Puri A. Clinicopathologic features of undifferentiated round cell sarcomas of bone & soft tissues: an attempt to unravel the BCOR-CCNB3- & CIC-DUX4-positive sarcomas. Indian J Med Res 2019; 150 (06) 557-574
  • 27 Siegele B, Roberts J, Black JO, Rudzinski E, Vargas SO, Galambos C. DUX4 immunohistochemistry is a highly sensitive and specific marker for CIC-DUX4 fusion-positive round cell tumor. Am J Surg Pathol 2017; 41 (03) 423-429
  • 28 Bosnakovski D, Ener ET, Cooper MS. et al. Inactivation of the CIC-DUX4 oncogene through P300/CBP inhibition, a therapeutic approach for CIC-DUX4 sarcoma. Oncogenesis 2021; 10 (10) 68
  • 29 Lin YK, Wu W, Ponce RK, Kim JW, Okimoto RA. Negative MAPK-ERK regulation sustains CIC-DUX4 oncoprotein expression in undifferentiated sarcoma. Proc Natl Acad Sci U S A 2020; 117 (34) 20776-20784